Study of side effect reduction of anticancer agents by regulation of exogenous gene expression
| Project/Area Number |
20790152
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Himeji Dokkyo University |
|---|
Principal Investigator |
KINOSHITA Atsushi Himeji Dokkyo University, 薬学部, 講師 (60454766)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 医療薬剤学 / 遺伝子治療 / 抗悪性腫瘍薬 / 遺伝子発現制御 / CMVプロモーター / フリーラジカルスカベンジャー / 活性酸素種 / MAPK / 抗悪件腫瘍薬 |
|---|
| Research Abstract |
For the purpose of regulation of transgene expression after gene introduction in gene therapy, the levels of CMV-promoter-driven transgene expression was analyzed when transgene introduced cells was exposed by anticancer agents. The levels of CMV-promoter-driven transgene expression were increased by doxorubicin (Dox) exposure. The induction of CMV-promoter-driven transgene expression by Dox was decreased by co-treatment of edaravone. We also found that phosphorylation pathway of AP-1 having CMV-promoter binding ability was activated by Dox.
|
Report
(4 results)
Research Products
(10 results)
